Resistance to antiretroviral drugs remains an important limitation to successful human
immunodeficiency virus type 1 (HIV-1) therapy. Resistance testing can improve treatment …

A significant obstacle to the efficacy of drugs directed against viral targets is the presence of
amino acid polymorphisms in the targeted molecules. Amino acid polymorphisms may occur …

HIV-1 protease is one of the major antiviral targets in the treatment of patients infected with
HIV-1. The nine FDA approved HIV-1 protease inhibitors were developed with extensive use …

Background People with HIV-1 in low-income and middle-income countries increasingly
need second-line regimens with boosted protease inhibitors. However, data are scarce for …

HIV-1 protease is an essential enzyme for viral particle maturation and is a target in the fight
against HIV-1 infection worldwide. Several natural polymorphisms are also associated with …

A series of HIV-1 protease mutants has been designed in an effort to analyze the
contribution to drug resistance provided by natural polymorphisms as well as therapy …

Protease inhibitors are key components in the chemotherapy of HIV-1 infection. However,
the long term efficacy of antiretroviral therapies is hampered by issues of patient compliance …

HIV-1 protease is essential for the production of mature, infectious virions and is a major
target in antiretroviral therapy. We successfully purified a HIV-1 subtype C variant, L38↑ …

The HIV protease plays a major role in the life cycle of the virus and has long been a target
in antiviral therapy. Resistance of HIV protease to protease inhibitors (PIs) is problematic for …

Acquired immunodeficiency syndrome (AIDS) is one of the most challenging infectious
diseases to treat on a global scale. Understanding the mechanisms underlying the …